A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nabpaclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer

被引：0
|
作者：
Vincent, Picozzi [1 ]
Vaibhav, Sahai [2 ]
Diane, Simeone [2 ]
Caio, Rocha Lima [3 ]
Allyson, Ocean [4 ]
Philip, Philip [5 ]
Wasif, Saif [6 ]
Aparna, Kalyan [7 ]
Michael, Ondovik [8 ]
Jack, Shiansong Li [8 ]
Chrystal, Louis [8 ]
机构：
[1] Virginia Mason, Seattle, WA USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Gibbs Canc Ctr, Res Inst, Spartanburg, SC USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Karmanos Canc Ctr, Detroit, MI USA
[6] Tufts Med Ctr, Boston, MA USA
[7] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[8] Celgene Corp, Summit, NJ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study
    Vincent, Picozzi
    Caio, Rocha Lima
    Vaibhav, Sahai
    Diane, Simeone
    Allyson, Ocean
    Philip, Philip
    Wasif, Saif
    Aparna, Kalyan
    Michael, Ondovik
    Jack, Shiansong Li
    Victoria, Manax
    ANNALS OF ONCOLOGY, 2016, 27 : 83 - 84
  • [2] Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results
    Sahai, V.
    Saif, W.
    Kalyan, A.
    Philip, P.
    Rocha-Lima, C.
    Ocean, A.
    Ondovik, M.
    Simeone, D.
    Karnoub, M.
    Louis, C.
    Picozzi, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer
    Sahai, Vaibhav
    Saif, M. Wasif
    Kalyan, Aparna
    Philip, Philip A.
    Rocha-Lima, Caio M.
    Ocean, Allyson
    Ondovik, Michael S.
    Simeone, Diane M.
    Banerjee, Sibabrata
    Bhore, Rafia
    Louis, Chrystal U.
    Picozzi, Vincent
    JOURNAL OF PANCREATIC CANCER, 2019, 5 (01) : 35 - 42
  • [4] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Cavanna, Luigi
    Artioli, Fabrizio
    Codignola, Claudio
    Lazzaro, Antonio
    Rizzi, Anna
    Gamboni, Alessandro
    Rota, Luigina
    Rodino, Carmelina
    Boni, Fabrizio
    Iop, Aldo
    Zaniboni, Alberto
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
  • [5] Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC).
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Bernuzzi, P
    Bertè, R
    Bidin, L
    Palladino, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 330S - 330S
  • [6] Metronomic therapy with 5-FU, weekly nab-paclitaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: A phase II study.
    Isacoff, William H.
    Reber, Howard A.
    Hines, Oscar J.
    Donahue, Timothy R.
    Purcell, Fay M.
    Clerkin, Barbara M.
    Clerkin, Kara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in previously treated patients with advanced metastatic gastric cancer
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Anselmi, E
    Bidin, L
    Palladino, M
    Rodinò, C
    ANNALS OF ONCOLOGY, 2005, 16 : 323 - 323
  • [8] 5-Fluorouracil (5-FU) plus leucovorin versus 5-FU leucovorin plus interferon-A given as adjuvant chemotherapy in colon cancer
    Papacostas, P
    Stathopoulos, GP
    Malamos, NA
    Michailakis, E
    Rigatos, S
    Golematis, B
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 752 - 752
  • [9] A phase 1/2, open -label, dose -expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
    Wainberg, Z.
    Boland, P.
    Lieu, C.
    Dayyani, F.
    Macarulla, T.
    Zhang, B.
    Belanger, B.
    Moore, Y.
    Wang, T.
    Maxwell, F.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients
    Si Sun
    Lei Ping Wang
    Jian Zhang
    Xiao Yan Yang
    Qun Ling Zhang
    Zhen Jia
    Xi Chun Hu
    Bi Yun Wang
    Medical Oncology, 2012, 29 : 418 - 424
12345